Saliva Versus Plasma Therapeutic Drug Monitoring of Valproic Acid in Jordanian Patients.


Journal

Drug research
ISSN: 2194-9387
Titre abrégé: Drug Res (Stuttg)
Pays: Germany
ID NLM: 101602406

Informations de publication

Date de publication:
19 Jul 2024
Historique:
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: aheadofprint

Résumé

Therapeutic drug monitoring is used to ensure that medications are prescribed and administered according to safe doseage advice and for the purpose of achieving the desired therapeutic effects in patients. Several methods are used to perform therapeutic drug monitoring. However, there is insufficient evidence to currently support therapeutic drug monitoring of Valproic acid using salivary samples. The aim of this paper is to determine the feasibility of using salivary samples as a substitute for plasma samples for therapeutic drug monitoring of Valproic acid. In this study a total of 23 patients participated, with the mean age of 33.39. Salivary and plasma samples were collected and analysed to determine the peak and trough concentrations of Valproic acid for comparison between the two methods. Calibrated LC- MS/ MS was used to measure Valproic acid levels. Statistical analyses were performed using ANOVA test and ethical approval was obtained prior to sample collection. The results showed that saliva Valproic acid levels were less than that of plasma levels. There was no significant correlation between saliva and plasma level of Valproic acid (P>0.05). However, there was a significant correlation between the area under the curve for both saliva and plasma Valproic acid (P<0.05). Creatinine clearance was significantly correlated with peak plasma levels of Valproic acid (P<0.05). Albumin was significantly correlated with plasma levels of Valproic acid. There was also a significantly positive and moderate relationship between Log Saliva Cmax and Log plasma free Valproic acid concentration (r=0.76, p<0.018). In conclusion, saliva samples can be used as a substitute for plasma samples in the therapeutic drug monitoring of Valproic acid.

Identifiants

pubmed: 39029516
doi: 10.1055/a-2357-8095
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Nasir Idkaidek (N)

Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan.

Aya Al-Tarawneh (A)

Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan.
Albasheer Hospital, Amman, Jordan.

Laith Alshoaibi (L)

Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan.
Albasheer Hospital, Amman, Jordan.

Haya Tuffaha (H)

Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan.

Asma Zinati (A)

Albasheer Hospital, Amman, Jordan.

Majed Abdelqader (M)

Albasheer Hospital, Amman, Jordan.

Ahmad Al-Ghazawi (A)

Triumpharma LLC, Amman, Jordan.

Ayman Rabayah (A)

Triumpharma LLC, Amman, Jordan.

Salim Hamadi (S)

Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan.

Classifications MeSH